


Federal Circuit Opens Door for PTAB Institution Decision Appeals

No Longer the Stuff of Science Fiction: The FDA’s New Policy Approach to Regenerative Medicine Products

Shire v. Amneal – Compound Claim Not Obvious and API Supplier Not Liable Under FDA Safe Harbor

Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB

Teaching Away Negated by References Disclosing How to Offset Disadvantages

For BioPharma, Citing Relevant Art During Prosecution Does Not Appear to Minimize IPR Risk

Does the scope of immunity from assertions of patent infringement against U.S. government contractors under 28 U.S.C. § 1498 extend to acts of indirect infringement?
Connect: Email
Subscribe: Subscribe via RSS